MARVELD1 and colorectal carcinoma: To address the underlying mechanism by which patients with high MARVELD1 expression present poorer overall survival, we investigated the correlation between endogenous MARVELD1 expression and the IC50 of clinical first-line medications (oxaliplatin, irinotecan and 5-fluorouracil) using CRC cell lines.